Susanne Wegmann

Dr. Susanne Wegmann

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2018 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
SWSusanne Wegmann
Susanne Wegmann
BEBahareh Eftekharzadeh
Bahareh Eftekharzadeh
KTKatharina Tepper
Katharina Tepper
KZKatarzyna M Zoltowska
Katarzyna M Zoltowska
RBRachel E Bennett
Rachel E Bennett
BHBradley T Hyman
Bradley T Hyman
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

1 April 2020 in Nature
Verified
Journal Article
Closed access
PDF file
JRJennifer N. Rauch
Jennifer N. Rauch
GLGabriel Luna
Gabriel Luna
EGElmer Guzman
Elmer Guzman
MAMorgane Audouard
Morgane Audouard
CCCollin Challis
Collin Challis
KKKenneth S. Kosik
Kenneth S. Kosik

1 August 2021 in Current Opinion in Neurobiology
Verified
Journal Article
Open access
SWSusanne Wegmann
Susanne Wegmann
JBJacek Biernat
Jacek Biernat
EMEckhard Mandelkow
Eckhard Mandelkow
The functions of the neuronal microtubule-associated protein Tau in the central nervous system are regulated by manifold posttranslational modifications at more than 50 sites. Tau in healthy neurons carries multiple phosphate groups, mostly in its microtubule assembly domain. Elevated phosphorylation and aggregation of Tau are widely considered pathological hallmarks in Alzheimer's disease (AD) and other tauopathies, triggering the quest for Tau posttranslational modifications in the disease context. However, the phosphorylation patterns of physiological and pathological Tau are surprisingly similar and heterogenous, making it difficult to identify specific modifications as therapeutic targets and biomarkers for AD. We present a concise summary of - and view on - important previous and recent advances in Tau phosphorylation analysis in the context of AD.

24 March 2015 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
APAmy M Pooler
Amy M Pooler
MPManuela Polydoro
Manuela Polydoro
EMEduardo A Maury
Eduardo A Maury
SNSamantha B Nicholls
Samantha B Nicholls
SRSnigdha M Reddy
Snigdha M Reddy
BHBradley T Hyman
Bradley T Hyman
In early stages of Alzheimer’s disease (AD), neurofibrillary tangles (NFT) are largely restricted to the entorhinal cortex and medial temporal lobe. At later stages, when clinical symptoms generally occur, NFT involve widespread limbic and association cortices. At this point in the disease, amyloid plaques are also abundantly distributed in the cortex. This observation from human neuropathological studies led us to pose two alternative hypotheses: that amyloid in the cortex is permissive for the spread of tangles from the medial temporal lobe, or that these are co-occurring but not causally related events simply reflecting progression of AD pathology. We now directly test the hypothesis that cortical amyloid acts as an accelerant for spreading of tangles beyond the medial temporal lobe. We crossed rTgTauEC transgenic mice that demonstrate spread of tau from entorhinal cortex to other brain structures at advanced age with APP/PS1 mice, and examined mice with either NFTs, amyloid pathology, or both. We show that concurrent amyloid deposition in the cortex 1) leads to a dramatic increase in the speed of tau propagation and an extraordinary increase in the spread of tau to distal brain regions, and 2) significantly increases tau-induced neuronal loss. These data strongly support the hypothesis that cortical amyloid accelerates the spread of tangles throughout the cortex and amplifies tangle-associated neural system failure in AD.

14 April 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
BCBenjamin Caballero
Benjamin Caballero
MBMathieu Bourdenx
Mathieu Bourdenx
ELEnrique Luengo
Enrique Luengo
ADAntonio Diaz
Antonio Diaz
PSPeter Dongmin Sohn
Peter Dongmin Sohn
ACAna Maria Cuervo
Ana Maria Cuervo
Disrupted homeostasis of the microtubule binding protein tau is a shared feature of a set of neurodegenerative disorders known as tauopathies. Acetylation of soluble tau is an early pathological event in neurodegeneration. In this work, we find that a large fraction of neuronal tau is degraded by chaperone-mediated autophagy (CMA) whereas, upon acetylation, tau is preferentially degraded by macroautophagy and endosomal microautophagy. Rerouting of acetylated tau to these other autophagic pathways originates, in part, from the inhibitory effect that acetylated tau exerts on CMA and results in its extracellular release. In fact, experimental blockage of CMA enhances cell-to-cell propagation of pathogenic tau in a mouse model of tauopathy. Furthermore, analysis of lysosomes isolated from brains of patients with tauopathies demonstrates similar molecular mechanisms leading to CMA dysfunction. This study reveals that CMA failure in tauopathy brains alters tau homeostasis and could contribute to aggravate disease progression.

22 February 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
PAPeter E. A. Ash
Peter E. A. Ash
SLShuwen Lei
Shuwen Lei
JSJenifer Shattuck
Jenifer Shattuck
SBSamantha Boudeau
Samantha Boudeau
YCYari Carlomagno
Yari Carlomagno
BWBenjamin Wolozin
Benjamin Wolozin
Significance: Phase separation of proteins is increasingly thought to play a fundamental role in biological processes. Recent studies show that tau protein phase separates, but the biological significance is unknown since artificial crowding agents are typically used and the resulting tau is not toxic. We now demonstrate that TIA1 potentiates RNA-mediated phase separation of tau, thereby enabling a process that occurs at physiological concentrations and also directs the formation of biologically active, highly neurotoxic oligomeric tau. Coordinated phase separation of functionally related proteins provides a general mechanism through which membraneless organelles can direct biological activities.